Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012

2018 ◽  
Vol 101 ◽  
pp. 77-86 ◽  
Author(s):  
C. Schroten-Loef ◽  
R.H.A. Verhoeven ◽  
I.H.J.T. de Hingh ◽  
A.J. van de Wouw ◽  
H.W.M. van Laarhoven ◽  
...  
Keyword(s):  
The Netherlands ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Survival Times ◽  
Unknown Primary Carcinoma

Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study

2000 ◽  
Vol 18 (17) ◽  
pp. 3101-3107 ◽  
Author(s):  
Evangelos Briasoulis ◽  
Haralambos Kalofonos ◽  
Dimitris Bafaloukos ◽  
Epaminondas Samantas ◽  
George Fountzilas ◽  
...  
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Area Under The Curve ◽  
Multiple Organ ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Target Area ◽  
Pleural Disease ◽  
Survival Times ◽  
Pleural Metastases ◽  
Unknown Primary Carcinoma

PURPOSE: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP).PATIENTS AND METHODS: Seventy-seven consecutive CUP patients (45 women and 32 men; median age, 60 years) were treated with carboplatin at target area under the curve 6 mg/mL/min followed by paclitaxel 200 mg/m2as a 3-hour infusion and granulocyte colony-stimulating factor from days 5 to 12. Treatment courses were repeated every 3 weeks to a maximum of eight cycles. Forty-seven patients had adenocarcinomas, 27 had undifferentiated carcinomas, and three had squamous cell carcinomas. Thirty-three patients presented with liver, bone, or multiple organ metastases, 23 with predominantly nodal/pleural disease, and 19 (16 women) with peritoneal carcinomatosis.RESULTS: The overall response rate by intent-to-treat analysis was 38.7% (95% confidence interval, 27.5% to 49.9%). There were no differences in response between adenocarcinomas and undifferentiated carcinomas, but efficacy varied among clinical subsets. The response rates and median survival times in the three clinically defined subsets were 47.8% and 13 months, respectively, for patients with predominantly nodal/pleural disease, 68.4% and 15 months, respectively, in women with peritoneal carcinomatosis, and 15.1% and 10 months, respectively, in patients with visceral or disseminated metastases. Chemotherapy was well-tolerated.CONCLUSION: Carboplatin plus paclitaxel combination chemotherapy is effective in patients with predominantly nodal/pleural metastases of unknown primary carcinoma and in women with peritoneal carcinomatosis. However, in patients with liver, bone, or multiple organ involvement, the combination offers limited benefit. The investigation of novel treatment approaches is highly warranted for this group of patients.

Narrow band imaging in head and neck unknown primary carcinoma: A systematic review and meta‐analysis

2019 ◽  
Vol 130 (7) ◽  
pp. 1692-1700 ◽  
Author(s):  
Pasquale Di Maio ◽  
Oreste Iocca ◽  
Armando Virgilio ◽  
Marco Giudice ◽  
Raul Pellini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Meta Analysis ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Unknown Primary Carcinoma

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

1997 ◽  
Vol 15 (5) ◽  
pp. 2056-2066 ◽  
Author(s):  
R Lenzi ◽  
K R Hess ◽  
M C Abbruzzese ◽  
M N Raber ◽  
N G Ordoñez ◽  
...  
Keyword(s):  
Median Survival ◽  
Proportional Hazards ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Entire Group ◽  
Poorly Differentiated Adenocarcinoma ◽  
Prognostic Features ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Unknown Primary Carcinoma

PURPOSE The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA). PATIENTS AND METHODS The 1,400 patients analyzed were referred to our unknown-primary tumor (UPT) clinic from January 1, 1987 through July 31, 1994. Clinical data from these patients were entered into a computerized data base for storage, retrieval, and analysis. Survival was measured from the time of diagnosis; survival distribution was estimated using the product-limit method. Multivariate survival analyses were performed using proportional hazards regression and by recursive partitioning. RESULTS Nine hundred seventy-seven patients were diagnosed with unknown-primary carcinoma (UPC) and 337 of these patients had PDC or PDA. No clinical differences were identified among patients with PDC, PDA, or UPC patients with other carcinoma or adenocarcinoma subtypes. PDC patients enjoyed better survival than PDA patients. Poor cellular differentiation was not an important prognostic variable. Variables predictive of survival included lymph node metastases, sex, number of metastatic sites, histology (PDC v PDA), and age. Although chemotherapy did not appear to influence survival for the entire group of PDC or PDA patients, a subset of patients with good prognostic features experienced median survival durations of up to 40 months. CONCLUSION The long median survival and chemotherapy responsiveness of UPC patients with PDC and PDA could not be confirmed. However, subpopulations with prolonged median survival durations could be defined, and the value of chemotherapy in this group remains to be determined. Identification and exclusion of treatable or slow-growing malignancies may account for the poor survival of the PDC and PDA patients reported in this study.

scholarly journals Clinical Analysis of Cervical Lymph Node Metastasis from an Unknown Primary Carcinoma

2008 ◽  
Vol 111 (12) ◽  
pp. 734-738 ◽  
Author(s):  
Tadashi Yoshii ◽  
Hidenori Inohara ◽  
Shiro Akahani ◽  
Yoshifumi Yamamoto ◽  
Yoichiro Tomiyama ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Clinical Analysis ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Node Metastasis ◽  
Unknown Primary Carcinoma

scholarly journals Clinical Study of 28 Cases of Cervical Lymph Node Metastasis from an Unknown Primary Carcinoma

2007 ◽  
Vol 110 (7) ◽  
pp. 506-512 ◽  
Author(s):  
Takamasa Tagawa ◽  
Toshiki Tomita ◽  
Hiroshi Yamaguchi ◽  
Hiroyuki Ozawa ◽  
Koji Sakamoto ◽  
...  
Keyword(s):  
Lymph Node ◽  
Clinical Study ◽  
Lymph Node Metastasis ◽  
Cervical Lymph Node ◽  
Cervical Lymph Node Metastasis ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Node Metastasis ◽  
Unknown Primary Carcinoma
Sign in / Sign up

Export Citation Format

Share Document